[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100275322":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":43,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":10,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Humanity and Health Research Centre","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"CHB Group",null,"Patients with chronic hepatitis B",{"label":13,"type":10,"description":14,"interventionNames":10},"CHB\u002FNAFLD Group","Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease",{"label":16,"type":10,"description":17,"interventionNames":10},"NAFLD Group","Patients with nonalcoholic fatty liver disease",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"George Lau, MD","CONTACT","+852 2861 3777","gkklau@netvigator.com",[25],{"facility":26,"status":27,"city":28,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Humanity and Health GI and Liver Centre","RECRUITING","Hong Kong","00852","China",{"type":32,"coordinates":33},"Point",[34,35],114.17469,22.27832,{"lat":35,"lon":34},[38,41],{"name":39,"role":21,"phone":40,"phoneExt":10,"email":23},"George KK Lau, MD","(852)28613777",{"name":39,"role":42,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100275322",false,"NCT02863757","Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease","Disease Progression and Clinical Outcomes in Chronic Hepatitis B (CHB) Patients With Comorbid Nonalcoholic Fatty Liver Disease (NAFLD)","Inclusion Criteria:\n\n* Liver biopsy proved CHB and\u002For NAFLD at baseline;\n* Chinese\n* Follow-up duration\\>12 months\n\nExclusion Criteria:\n\n* Other liver diseases;\n* Secondary causes of hepatic steatosis;\n* Alcohol abuse;\n* Liver cirrhosis, cirrhosis related complications or HCC at baseline;\n* Malignancy;\n* History of liver transplantation","ALL",{"count":53,"type":54},1500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine the disease progression in CHB\u002FNAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).",[58,59],"Chronic Hepatitis B","Nonalcoholic Fatty Liver Disease","2025-03-20",{"date":62,"type":63},"2025-03-24","ACTUAL",{"date":65,"type":63},"2016-08-01",{"date":67,"type":54},"2026-12",{"name":5,"class":6},1]